Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IXICO plc (PHYOF)
London, GL, GB
Headquartered in London, United Kingdom, IXICO plc specializes in providing sophisticated data analytics services to the global biopharmaceutical industry. Its operational reach extends across the United Kingdom, Switzerland, the Netherlands, Ireland, other European countries, and the United States. The company's core offerings encompass the entire lifecycle of clinical study data, from its meticulous acquisition and analysis to its systematic management and comprehensive reporting. IXICO features proprietary technologies like Assessa, a robust, web-based digital platform that facilitates precise patient selection for trials and supports vital post-marketing surveillance. Another significant platform is TrialTracker, which offers specialized imaging services. This system is engineered to streamline the intricate imaging workflow, overseeing everything from image ingestion and quality assurance to expert reading, analysis, reporting, and secure data transfer. IXICO focuses its expertise primarily on neurological disorders. These include major conditions such as Alzheimer's, Parkinson's, and Huntington's, alongside Multiple Sclerosis and other demyelinating conditions, Progressive Supranuclear Palsy, and a range of other rare neurological diseases. Beyond its platform offerings, IXICO provides a comprehensive suite of services. These include specialized analytics for drug development, dedicated imaging operation support, and expert consultancy. Furthermore, it delivers complete, 'end-to-end' project support for clinical trials, encompassing initial trial design and consultation, robust project management, the establishment and oversight of imaging sites, comprehensive data management, meticulous reading and analysis, and guidance through the complex regulatory pathway. Established in 1995, IXICO plc continues to innovate within its field.
3 articles
- IXICO lifts revenue forecast on contract wins and wider client base Proactive Investors
- IXICO lifts revenue forecast on contract wins and wider client base - UPDATE Proactive Investors - Finance
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +2,233.33% | -94.78% | -86.00% | -97.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+13.3% ★ Q1'26: +56.0% (vs Q1'24)
-
EPS growth Biotechnology: +29.7%+55.3% ★ Q1'26: +58.6% (vs Q1'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-18.9% Q1'26: -35.1% (vs Q1'24)
-
EBIT margin Biotechnology: +0.0%-37.2% Q1'26: -31.4% (vs Q1'24)
-
ROIC Biotechnology: -16.1%-29.0% Q1'26: -36.6% (vs Q1'24)
-
Share dilution Biotechnology: -3.4%+85.2% Q1'26: +91.7% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.09× Q1'26: -0.14× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 1 Rev. Ana. 1 EPS Ana. |
Sep 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.12M
est: 4.73M (-34.2%)
|
3.27M
est: 5.50M (-40.6%)
|
4.10M
est: 4.96M (-17.4%)
|
5.39M
est: 7.05M (-23.5%)
|
7.56M
est: 9.37M (-19.3%)
|
9.53M
est: 12.28M (-22.4%)
|
9.19M
est: 12.39M (-25.9%)
|
8.64M
est: 9.60M (-9.9%)
|
6.67M
est: 7.96M (-16.3%)
|
5.77M
est: 5.50M (+4.9%)
|
6.53M
est: 6.49M (+0.6%)
|
7.49M
7.49M – 7.49M
+15.3% YoY
|
8.98M
8.98M – 8.98M
+20.0% YoY
|
| EBITDA |
-1.17M
est: -74.5K (-1,470.0%)
|
-1.82M
est: -86.5K (-2,000.7%)
|
-1.24M
est: -78.1K (-1,486.7%)
|
-659.0K
est: -110.9K (-494.3%)
|
323.0K
est: -147.3K (+319.3%)
|
1.29M
est: -193.2K (+769.8%)
|
1.31M
est: -195.0K (+770.4%)
|
750.0K
est: -151.0K (+596.8%)
|
-707.0K
est: -125.2K (-464.8%)
|
-1.95M
est: -575.8K (-237.8%)
|
-2.02M
est: -680.5K (-197.1%)
|
-784.3K
-784.3K – -784.3K
-15.3% YoY
|
-941.2K
-941.2K – -941.2K
-20.0% YoY
|
| EBIT |
-1.32M
est: -373.8K (-252.6%)
|
-2.37M
est: -434.2K (-445.8%)
|
-1.37M
est: -392.0K (-250.3%)
|
-786.0K
est: -556.7K (-41.2%)
|
364.0K
est: -739.5K (+149.2%)
|
856.0K
est: -969.8K (+188.3%)
|
1.12M
est: -978.7K (+214.2%)
|
908.0K
est: -757.9K (+219.8%)
|
-1.33M
est: -628.4K (-112.0%)
|
-2.15M
est: -941.9K (-128.7%)
|
-2.43M
est: -1.11M (-118.6%)
|
-1.28M
-1.28M – -1.28M
-15.3% YoY
|
-1.54M
-1.54M – -1.54M
-20.0% YoY
|
| Net Income |
-1.19M
est: -9.66M (+87.6%)
|
-2.12M
est: -6.09M (+65.2%)
|
-1.54M
est: -4.39M (+65.0%)
|
-668.0K
est: -2.23M (+70.0%)
|
432.0K
est: 268.6K (+60.9%)
|
952.0K
est: 1.34M (-29.2%)
|
1.51M
est: 2.39M (-36.8%)
|
1.03M
est: 1.33M (-22.2%)
|
-1.18M
est: -2.33M (+49.5%)
|
-2.00M
est: -4.11M (+51.3%)
|
-1.65M
est: -2.15M (+23.0%)
|
-892.9K
-892.9K – -892.9K
+58.4% YoY
|
-785.8K
-785.8K – -785.8K
+12.0% YoY
|
| SGA |
2.77M
est: 2.46M (+12.8%)
|
2.92M
est: 2.85M (+2.3%)
|
3.13M
est: 2.58M (+21.5%)
|
3.21M
est: 3.66M (-12.4%)
|
3.90M
est: 4.86M (-19.9%)
|
4.40M
est: 6.38M (-31.0%)
|
3.65M
est: 6.43M (-43.3%)
|
3.81M
est: 4.98M (-23.6%)
|
3.67M
est: 4.13M (-11.3%)
|
4.31M
est: 3.05M (+41.5%)
|
4.16M
est: 3.60M (+15.5%)
|
4.15M
4.15M – 4.15M
+15.3% YoY
|
4.98M
4.98M – 4.98M
+20.0% YoY
|
| EPS |
-0.08
est: -0.11 (+26.6%)
|
-0.09
est: -0.07 (-27.7%)
|
-0.06
est: -0.05 (-16.4%)
|
-0.02
est: -0.02 (+19.7%)
|
0.01
est: 0.00 (+206.5%)
|
0.02
est: 0.02 (+34.5%)
|
0.03
est: 0.03 (+18.6%)
|
0.02
est: 0.01 (+44.3%)
|
-0.02
est: -0.03 (+6.4%)
|
-0.04
est: -0.05 (+9.9%)
|
-0.02
est: -0.02 (+22.9%)
|
-0.01
-0.01 – -0.01
+58.4% YoY
|
-0.01
-0.01 – -0.01
+12.0% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Derek Lionel Glendon Hill | Co-Founder and President of Regulatory Science & External Relations | 521.7K | — |
| Bram Goorden | Chief Executive Officer & Director | 409.8K | male |
| Grant Nash | CFO, COO, Company Secretary & Executive Director | 307.4K | male |
| Hannah Esfahanian | HR Manager | — | female |
| James Chandler | Chief Business Officer | — | male |
| Joseph Hajnal | Co-Founder & Member of Scientific Advisory Board | — | — |
| Mark Austin | Chief Technology Officer | — | male |
| Robin Wolz | Chief Scientific Officer | — | — |
| Daniel Rueckert | Co-Founder & Member of Scientific Advisory Board | — | — |
| David Hawkes | Co-Founder & Member of Scientific Advisory Board | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PHYOF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
